Mannitol Fresenius 15%

Quick links

Choose a section

Quick links to important sections

Advertisements

Mannitol Fresenius 15%

Advertisements
Advertisements

Overview of Mannitol Fresenius 15%

Quick Facts

Property Description
Active Ingredient Mannitol (D-Mannitol)
Form Sterile Solution for Infusion
Pharmacological Class Osmotic Diuretic
General Purpose Rapid reduction of elevated internal pressure
Origin Derived Polyol (Sugar Alcohol)

Defining Mannitol Fresenius 15%: Identity and Class

Mannitol Fresenius 15% is a sterile, single-ingredient preparation whose active compound is Mannitol, which is classified as an Osmotic Diuretic agent. This medication is utilized in acute clinical environments where rapid fluid management is critical. Chemically, Mannitol is a sugar alcohol or polyol (D-Mannitol), naturally occurring but purified for pharmaceutical use, placing its origin as derived rather than purely synthetic. The preparation is distinguished by its use in hospital settings for emergency pressure management, rather than standard chronic therapy.

The Pharmaceutical Form and Composition of Mannitol 15%

The specific preparation is a hyperosmolar crystalloid solution, meaning it has a solute concentration significantly greater than that of normal plasma. It consists of D-Mannitol at a specific 15% weight per volume (w/v) concentration, dissolved completely in an aqueous vehicle (Water for Injection). The 15% w/v concentration is delivered as a parenteral intravenous solution for infusion, which is essential for ensuring rapid systemic action. Mannitol injection is indicated as an osmotic diuretic for the promotion of diuresis, confirming its high-level function of increasing fluid elimination.

The General Therapeutic Purpose of Osmotic Action

The general goal of this osmotic agent is the rapid mobilization of excess fluid from body tissues, serving as a physical mechanism to control abnormally elevated pressure within confined anatomical spaces. When infused, Mannitol molecules create a powerful osmotic pressure gradient, which efficiently draws free water out of specific tissues and into the circulation. This critical action allows the drug to achieve its core benefit: the acute control of dangerously high pressure associated with tissue swelling, particularly in areas like the brain and eye.

Regulatory References

  1. Mannitol (Osmitrol) Clinical Review
Advertisements

What side effects are possible with Mannitol Fresenius 15%?

Possible side effects and safety information

The official safety profile for Mannitol injection is primarily structured around the risk of fluid and electrolyte imbalance and potential complications related to volume expansion, as documented by governmental regulatory authorities like the FDA and EMA.

Adverse reactions are classified into System-Organ Classes (SOCs) in regulatory texts, affecting several major systems:

  • Metabolism and Nutrition Disorders: Common reactions include disturbances in fluid and electrolytes, such as acidosis, hyponatremia, and hypokalemia.
  • Nervous System Disorders: Common effects include headache and dizziness. Serious concerns listed include convulsions and the risk of a rebound increase in intracranial pressure after the drug's osmotic effect subsides.
  • Cardiac and Vascular Disorders: Tachycardia, hypotension, and hypertension are documented. A major serious reaction listed is Pulmonary Congestion/Edema and Congestive Heart Failure, resulting from rapid plasma volume expansion.
  • Renal and Urinary Disorders: The risk of Osmotic Nephrosis leading to Acute Renal Failure is a serious adverse reaction, particularly associated with high doses or prolonged use, as stated in regulatory warnings.
  • General Disorders: Nausea, vomiting, thirst, chills, and fever are commonly documented.

Serious Safety Constraints

The official labeling mandates specific safety restrictions. Use is formally contraindicated in situations such as Established Anuria (non-responsive to a test dose), Severe Pulmonary Edema, Severe Dehydration, and most cases of Active Intracranial Bleeding. Special safety considerations are necessary for patients with pre-existing Renal Impairment or Severe Cardiac Disease due to the heightened risk of serious volume-related complications.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose of Mannitol Fresenius 15% as primarily resulting from an excessive volume or rate of infusion, which leads to severe physiological disturbances. Management is strictly symptomatic and supportive, as no specific antidote is known.

Documented Overdose Manifestations

Overdose may present with serious fluid and electrolyte disturbances, including hypervolemia (fluid overload) or hypovolemia (dehydration), and critical imbalances such as hypo/hypernatremia and metabolic acidosis. These disturbances can progress to severe Central Nervous System (CNS) toxicity, potentially manifesting as confusion, stupor, convulsions, or coma. Regulatory documents also specify acute kidney injury (including renal failure) and pulmonary edema as life-threatening outcomes associated with overdose.

Required Emergency Actions

Action/Requirement Official Statement
Immediate Action The infusion must be stopped immediately upon suspicion of overdose or if renal, cardiac, or pulmonary status worsens.
Urgent Medical Care Seek immediate medical attention for suspected overdose. Acute symptomatic hyponatremic encephalopathy is considered a medical emergency.
Supportive Treatment Management focuses on correction of fluid and electrolyte imbalances. Hemodialysis may be required to help eliminate large amounts of Mannitol in severe cases.

Population-Specific Notes

The risk of severe outcomes, including renal failure, is increased in patients with pre-existing renal disease. Furthermore, the risk of hyponatremia and subsequent CNS effects is heightened in children and elderly patients.

Advertisements

Therapeutic Uses of Mannitol Fresenius 15%

The solution is commonly applied in settings that involve a need for short-term symptomatic assistance in managing increased internal pressure. This treatment is commonly used when symptoms that create noticeable physiological strain and symptoms that interfere with daily functioning are present.

Mannitol 15% may be part of symptomatic management applied across domains where additional symptomatic support is needed for symptoms related to organ-specific functional stress in conditions like severe cerebral edema (brain swelling) or hemorrhagic events, ocular emergencies, and the oliguric phase of acute renal failure.

This medication helps address symptoms that create noticeable physiological strain and provides support that assists with maintaining functional stability by easing the impact of pressure-related symptoms. As a supportive therapeutic option, it is primarily used during phases when symptoms become temporarily overwhelming or more disruptive.


Quick Fact: Relief for Pressure-Driven Symptoms

Property Description
Primary Goal Provides support to ease the overall symptom burden of high internal pressure.
Key Scenarios Acute head injury, ocular emergencies, and supportive therapy for acute kidney strain.
Benefit Focus Assists with maintaining functional stability during episodes of heightened physiological stress.
Advertisements

Eligibility and Restrictions for Use

The official regulatory profile for Mannitol Fresenius 15% defines strict conditions for its use, including absolute prohibitions and restrictions based on the patient's acute status and organ function.


Populations for Whom Use is Contraindicated

Mannitol is absolutely contraindicated and must not be administered to patients with the following conditions, as stated in the regulatory labeling:

  • Well-established Anuria due to severe renal disease.
  • Severe Pulmonary Congestion or Frank Pulmonary Edema.
  • Severe Hypovolemia (severe dehydration).
  • Active Intracranial Bleeding (unless administration occurs during a craniotomy).
  • Known Hypersensitivity to Mannitol.

Age and Condition-Specific Eligibility

Population / Status Regulatory Restriction / Condition
Renal Impairment Requires a test dose; continued use is conditional on achieving adequate urine flow.
Cardiac Conditions Requires careful evaluation of cardiovascular status due to the risk of exacerbating heart failure.
Pregnancy Restricted; should be given only if clearly needed and caution is advised during lactation.
Pediatric Patients Dosage requirements are not established for children under 12 years of age.
Geriatric Patients Caution is advised due to the greater risk of age-related renal, cardiac, or pulmonary issues.

These official eligibility rules define clear boundaries for use based on acute patient physiology and official regulatory data.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Mannitol Fresenius 15% is defined by its action as an osmotic diuretic, which can lead to additive effects or conditions that increase the risk of toxicity from co-administered medicinal products, according to regulatory information.


Pharmacodynamic and Electrolyte-Mediated Interactions

Interacting Substance/Class Officially Documented Effect
Other Diuretics (e.g., Furosemide) May cause additive diuresis and potentiate the risk of renal failure. Co-administration should be avoided if possible.
Nephrotoxic Drugs (e.g., Cyclosporine, Aminoglycosides) Increases the risk of renal failure following Mannitol administration. Co-administration should be avoided if possible.
Neurotoxic Drugs (e.g., Aminoglycosides) May potentiate the Central Nervous System (CNS) toxicity of Mannitol. Co-administration should be avoided if possible.
Digitalis-like Drugs (e.g., Digoxin) Mannitol-induced hypokalemia (low potassium) increases the risk of Digitalis toxicity.

Altered Drug Elimination

Mannitol may increase the elimination and consequently decrease the effectiveness of medicinal products that are significantly eliminated through the kidneys. Specifically, use with Lithium may initially increase its elimination but may also raise the risk of lithium toxicity if the patient develops renal impairment or volume depletion.

Absence of Documented Interactions

Official regulatory documents do not list any formal contraindicated combinations based solely on drug-drug interaction risk. Furthermore, no specific interactions with food, alcohol, herbal products, or supplements are documented in the prescribing information.

Advertisements

Mechanism of Action

How Mannitol Fresenius 15% Works

Mannitol Fresenius 15% operates through a non-receptor-mediated, physical mechanism based entirely on the principle of osmosis. As an impermeant solute, it remains confined primarily to the bloodstream and extracellular fluid, creating a significant osmotic pressure gradient across biological barriers.

u1F30A Mobilizing Fluid Through Osmotic Gradients

The primary mechanistic domain involves the creation of a systemic hyperosmolar state in the plasma. This high solute concentration acts across semipermeable membranes, such as the Blood-Brain Barrier (BBB), drawing free water from the interstitial and intracellular spaces of the tissues into the circulation. This targeted fluid shift results in the mobilization of fluid volume from confined tissue spaces.

u1F9E0 Reducing Tissue Volume in Confined Systems

The key physiological consequence of the fluid mobilization is the reduction of tissue volume, particularly in areas like the brain and eye, where the contained fluid volume contributes to the pressure status. By physically withdrawing water from these tissues, Mannitol rapidly and directly leads to the decrease in internal fluid pressure, which results from the reduction in tissue volume.

u1F4A6 Excreting Mobilized Fluid via Osmotic Diuresis

Once filtered by the kidney, Mannitol is not reabsorbed, maintaining a sustained high osmotic concentration within the renal tubules (osmotic load). This physical presence prevents the kidney from reclaiming water, resulting in a pronounced free water diuresis (increased urine output) that excretes the mobilized fluid, which maintains the fluid volume shift initiated by the osmotic gradient.

Advertisements

Dosage and Administration Information

How Mannitol Fresenius 15% is Used

The administration of Mannitol Fresenius 15% involves specific procedures for its use in acute clinical environments. The medication is administered by intravenous infusion only, ensuring controlled, systemic delivery. Its high osmolality requires infusion to occur preferably into a large central vein.

Administration Guidelines

Feature Instruction
Route of Administration Intravenous (IV) infusion only.
Infusion Duration The dose must be infused over a period of 30 to 60 minutes.
Adult Dosing Range Total dosage typically ranges from 0.25 to 2.0 g/kg of body weight, with a recommended maximum of 200 g in 24 hours.
Preadministration Timing For pressure reduction before ocular surgery, the dose is administered 60 to 90 minutes preoperatively.
Renal Test Dose Patients with inadequate urine output must first receive a test dose of 0.2 g/kg over 3 to 5 minutes to confirm a suitable renal response prior to full treatment.

Required Handling and Preparation

The solution must be visually inspected for crystals before use, as the concentration may crystallize at lower temperatures. If crystals are observed, the product must be warmed and agitated to redissolve them, then cooled to body temperature for safe infusion. Furthermore, an administration set equipped with an in-line filter is mandatory to prevent the potential infusion of any residual undissolved particulate matter. The infusion must not be administered simultaneously with blood products through the same line due to incompatibility concerns.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Mannitol Fresenius 15%


Evidence for use in Elevated Intracranial Pressure (ICP) and Cerebral Edema

This section will summarize the structure of clinical research, including randomized controlled trials (RCTs) and systematic reviews, that examined change in mannitol on brain pressure and tracked subsequent neurological outcomes in critically ill patients.

Research has explored this agent in conditions characterized by high pressure inside the skull, such as cerebral edema following a severe head injury. This agent was evaluated in research primarily conducted in critically ill adult patients who were continuously monitored. Studies examined various outcomes monitoring physiological strain or stress, including the acute change in Intracranial Pressure (ICP) and related markers like Cerebral Perfusion Pressure (CPP). Reported outcomes for the effect on ICP were often short-term and assessed using physiological biomarkers, with fewer data points related to long-term patient recovery.

The evidence level varies (low to moderate) because follow-up durations were limited for long-term functional recovery, and comparative evidence is lacking for certain dosing strategies.


Evidence for use in Elevated Intraocular Pressure (IOP)

This part will outline the research landscape, consisting primarily of smaller-scale clinical trials and observational data, that has investigated change in pressure inside the eye for emergency situations or pre-surgical preparation.

Research examined the agent in the context of pressure inside the eye, with studies focusing on acute or disruptive episodes. These trials monitored the outcomes related to systemic or functional imbalance by measuring the absolute change in IOP in the hours following administration. Findings described short-term pressure measurements, which was observed in some studies in the context of surgical procedures or acute conditions. Sample sizes were modest in many of these investigations, and data for certain groups or complex ocular conditions remain insufficient.


Evidence for use in the Oliguric Phase of Acute Kidney Injury (AKI)

This area will describe the trials and meta-analyses that have explored the use of osmotic diuresis to measure changes in urine output and the associated outcomes related to kidney function and the need for dialysis in high-risk patient groups.

Research has explored this agent in acute conditions where kidney function is impaired, specifically during the oliguric phase. Studies monitored patterns of increase in urine output in some patient groups. However, evidence is limited and findings were mixed regarding the consistent impact on major clinical outcomes, such as the frequency of the need for Renal Replacement Therapy (Dialysis).


Research Gaps and Uncertainty: What Remains Unclear

This final segment will synthesize the key areas of uncertainty identified in the literature. Long-term effects are not fully established across all indications, as follow-up durations were limited in many trials. Findings were mixed regarding the relative performance of this agent when compared to similar osmotic solutions. Research provides context but not individual predictions, and data for certain groups like older, frail patients or those with pre-existing kidney issues remain insufficient.

Key Studies & References

  1. Acute Kidney Injury Following Mannitol Infusion in Neurosurgical Patients (Observational Study)
  2. Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes (Clinical Trial NCT01606787)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mannitol Fresenius 15% (FAQ)


Q: How quickly does Mannitol start working after administration?

Official product information indicates that the medication begins to reduce pressure inside the eye (intraocular pressure) shortly after the infusion begins. The maximum pressure-reducing effect is often observed within 60 to 90 minutes after the infusion is initiated.


Q: Is there research comparing Mannitol to hypertonic saline for brain swelling?

Regulatory summaries on the research evidence for Mannitol note that evidence is limited and that comparative data are lacking for certain dosing strategies. Official information notes that studies comparing Mannitol to other osmotic solutions have sometimes shown mixed findings regarding their relative clinical performance.


Q: What are the signs or symptoms of the serious side effect, osmotic nephrosis?

Osmotic nephrosis, a condition that can lead to acute kidney failure, is listed in official labeling as a serious adverse reaction. Regulatory warnings emphasize the need for close monitoring of kidney function, including blood urea nitrogen, serum creatinine, and urine output, for patients receiving Mannitol, particularly those at risk of developing kidney issues.


Q: What kind of filter is required for the IV administration set?

Regulatory documents state that when this medication is administered, the set must include an in-line filter. This requirement is necessary to help prevent the potential infusion of any residual particulate matter or undissolved crystals.


Q: How is the concentration of 15% w/v calculated?

Mannitol Fresenius 15% is prepared as a 15% weight per volume (15% w/v) solution. This formulation means that the solution contains 150 grams of the active Mannitol ingredient fully dissolved in one liter (1000 mL) of the aqueous vehicle (Water for Injection).


Q: How long does the pressure-reducing effect of Mannitol last?

The therapeutic effect of Mannitol is acute and short-lived. According to official drug information, the reduction in pressure is generally maintained for a period ranging from 3 to 8 hours after the infusion has been completed.


Q: What type of health care professional can administer this drug?

This medication is reserved for acute clinical settings due to its specialized use and administration route. It is administered by intravenous infusion only and requires the supervision and control of a healthcare provider in an acute clinical setting due to its specialized use.


Advertisements

How should Mannitol Fresenius 15% be stored and disposed of?

How to Store and Dispose of Mannitol Fresenius 15%

Mannitol Injection, USP (including 15% solutions) must be stored at Controlled Room Temperature, officially maintained between 20 C and 25 C (68 F to 77 F), and must be protected from freezing. Exposure to low temperatures can cause crystallization, which requires the container to be warmed to 70 C to redissolve the crystals; the solution must be discarded if crystals cannot be completely redissolved.

Only use the product if the solution is clear, the container is undamaged, and the seals are intact. The solution is for single use only. Any unused portion must be discarded immediately. Disposal of unused product and waste materials must be carried out according to local regulations for pharmaceutical waste. Store the medicine out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mannitol Fresenius 15% found in:

A-Z Index: